year 18, Issue 2 (March - April 2024)                   Iran J Med Microbiol 2024, 18(2): 5-5 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shahbazi T, Bakhshi B, Rasekhi A, Fazeli M S, Fallah F. Title: Significant Presence of Clostridioides difficile in Colorectal Cancer Patients by TaqMan Real-Time PCR. Iran J Med Microbiol 2024; 18 (2) :5-5
1- Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2- Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,
3- Division of Colon and Rectal Surgery, Department of Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
4- Tropical Infections Diseases Research Center, Department of Microbiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (145 Views)

Background and Objectives: This study aimed to analyze the potential contribution of Clostridioides difficile (C. difficile) to colorectal cancer (CRC) by comparing its presence in CRC patients and healthy individuals.
Methods: This study was conducted on 25 CRC patients referring to the colorectal department of a major hospital in Tehran from June 2011 to May 2012. CRC patients confirmed by colonoscopy and pathological examination underwent a cancer staging process according to the TNM staging system provided by the American Joint Committee on Cancer. Also, 25 healthy individuals serving as the control group were included. DNA was extracted from 500 mg of stool sample of each patient and healthy volunteer. TaqMan real-time PCR was performed on DNA samples to detect C. difficile DNA using specific primers and probe targeting the 16s rRNA gene. The mean of triplicate reactions were considered as the final Ct values.
Results: All patients were in stage III, and tumor location was recorded in the colon for all patients. In the CRC group, 20 individuals exhibited the presence of C. difficile, while in the control group, only 5 out of 25 people tested positive for this bacterium, and this difference was statistically significant (p< .001).
Conclusion: This study demonstrated a higher incidence of C. difficile in CRC patients compared to healthy individuals, suggesting that the presence of C. difficile may play a significant role in the progression of CRC. Early identification and management of CDI are crucial and challenging aspects of CRC patient care.

Type of Study: Original Research Article | Subject: Medical Bacteriology
Received: 2024/03/3 | Accepted: 2024/05/16 | ePublished: 2024/05/25

1. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI)-a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21(1):456. [DOI:10.1186/s12879-021-06147-y] [PMID] [PMCID]
2. Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med. 2018;18(3):237-41. [DOI:10.7861/clinmedicine.18-3-237] [PMID] [PMCID]
3. Sandhu BK, McBride SM. Clostridioides difficile. Trends Microbiol. 2018;26(12):1049-50. [DOI:10.1016/j.tim.2018.09.004] [PMID] [PMCID]
4. Vikash F, Vikash S, Kumar V, Taj S, Pan CW, Syed N, et al. S237 A Comparative Analysis of Clostridioides difficile Infection Outcomes in Hospitalizations With and Without Colorectal Cancer in the United States. J Am Coll Gastroenterol. 2023;118(10S):S177-8. [DOI:10.14309/01.ajg.0000950588.33647.62]
5. Danos DM, Ferguson TF, Simonsen NR, Leonardi C, Yu Q, Wu XC, et al. Neighborhood disadvantage and racial disparities in colorectal cancer incidence: a population-based study in Louisiana. Ann Epidemiol. 2018;28(5):316-21. [DOI:10.1016/j.annepidem.2018.02.004] [PMID] [PMCID]
6. Dekker E, Rex DK. Advances in CRC prevention: screening and surveillance. Gastroenterology. 2018;154(7):1970-84. [DOI:10.1053/j.gastro.2018.01.069] [PMID]
7. Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020;11:615056. [DOI:10.3389/fimmu.2020.615056] [PMID] [PMCID]
8. Jahani-Sherafat S, Azimirad M, Alebouyeh M, Amoli HA, Hosseini P, Ghasemian-Safaei H, et al. The rate and importance of Clostridium difficile in colorectal cancer patients. Gastroenterol Hepatol Bed Bench. 2019;12(4):358-63.
9. Magat EM, Balanag GA, CariÑo AM, Fellizar A, Ortin TS, Guevarra Jr L, et al. Clostridioides difficile antibody response of colorectal cancer patients versus clinically healthy individuals. Biosci Microbiota Food Health. 2020;39(3):123-7. [DOI:10.12938/bmfh.2020-010] [PMID] [PMCID]
10. Bassotti G, Stracci F, Marconi P, Fettucciari K. Clostridioides difficile and colorectal cancer: a dangerous liaison. Eur J Gastroenterol Hepatol. 2023;35(9):985-8. [DOI:10.1097/MEG.0000000000002615] [PMID]
11. Lawrence PF, Essentials of General Surgery and Surgical Specialties. 6th Ed. Lippincott Williams & Wilkins: Philadelphia, U.S. 2018.
12. American Joint Committee on Cancer, Cancer Programs. Validating science, improving patient care. 8th Edition Updates and Corrections. 2024. Access from: []
13. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. Vol. 1024. Springer: Cham, Switzerland. 2017. pp. XVII, 1032.
14. Li L, Li X, Zhong W, Yang M, Xu M, Sun Y, et al. Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apcmin/+ mice. EBioMedicine. 2019;48:301-15. [DOI:10.1016/j.ebiom.2018.11.043] [PMID] [PMCID]
15. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PloS One. 2013;8(8):e70803. [DOI:10.1371/journal.pone.0070803] [PMID] [PMCID]
16. Wren, M. (2010). Clostridium difficile Isolation and Culture Techniques. In: Mullany, P., Roberts, A.P. (eds). In Clostridium difficile. Methods in Molecular Biology™, Vol. 646. Humana Press: New Jersey, U.S. 2010. pp. 39-52. [DOI:10.1007/978-1-60327-365-7_3] [PMID]
17. Kubota H, Sakai T, Gawad A, Makino H, Akiyama T, Ishikawa E, et al. Development of TaqMan-based quantitative PCR for sensitive and selective detection of toxigenic Clostridium difficile in human stools. PLoS One. 2014;9(10):e111684. [DOI:10.1371/journal.pone.0111684] [PMID] [PMCID]
18. Kochakkhani H, Moosavy M H, Dehghan P. Isolation and identification of Clostridium difficile from ready-to-eat vegetable salads in restaurants of Tabriz by Real-time PCR and determination of the antibiotic resistance pattern. Sci J Kurdistan Univ Med Sci. 2017;22(3):102-12. [DOI:10.15171/PS.2016.31]
19. Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. 7th ed. Vol. 6. Pearson publication: Boston, MA. U.S. 2013.
20. Darbandi A, Mirshekar M, Shariati A, Moghadam MT, Lohrasbi V, Asadolahi P, Talebi M. The effects of probiotics on reducing the colorectal cancer surgery complications: a periodic review during 2007-2017. Clin Nutr. 2020;39(8):2358-67. [DOI:10.1016/j.clnu.2019.11.008] [PMID]
21. Redondo-Useros N, Nova E, González-Zancada N, Díaz LE, Gómez-Martínez S, Marcos A. Microbiota and lifestyle: a special focus on diet. Nutrients. 2020;12(6):1776. [DOI:10.3390/nu12061776] [PMID] [PMCID]
22. Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep. 2018;6(1):1-2. [DOI:10.1093/gastro/gox031] [PMID] [PMCID]
23. Hanus M, Parada-Venegas D, Landskron G, Wielandt AM, Hurtado C, Alvarez K, et al. Immune system, microbiota, and microbial metabolites: the unresolved triad in colorectal cancer microenvironment. Front Immunol. 2021;12:612826. [DOI:10.3389/fimmu.2021.612826] [PMID] [PMCID]
24. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66:462-70. [DOI:10.1007/s00248-013-0245-9] [PMID]
25. Abdelhalim MM, Saafan GS, El-Sayed HS, Ghaith DM. In vitro antibacterial effect of probiotics against Carbapenamase-producing multidrug-resistant Klebsiella pneumoniae clinical isolates, Cairo, Egypt. J Egypt Public Health Assoc. 2022;97(1):19. [DOI:10.1186/s42506-022-00114-4] [PMID] [PMCID]
26. Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q, Zhao P, et al. Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget. 2017;8(7):11877. [DOI:10.18632/oncotarget.14424] [PMID] [PMCID]
27. Fettucciari K, Fruganti A, Stracci F, Spaterna A, Marconi P, Bassotti G. Clostridioides difficile Toxin B Induced Senescence: A New Pathologic Player for Colorectal Cancer?. Int J Mol Sci. 2023;24(9):8155. [DOI:10.3390/ijms24098155] [PMID] [PMCID]
28. Fukugaiti MH, Ignacio A, Fernandes MR, Ribeiro Júnior U, Nakano V, Avila-Campos MJ. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients. Braz J Microbiol. 2015;46:1135-40. [DOI:10.1590/S1517-838246420140665] [PMID] [PMCID]
29. Geier DA, Geier MR. Colon Cancer Risk Following Intestinal Clostridioides difficile Infection: A Longitudinal Cohort Study. J Clin Med Res. 2023;15(6):310. [DOI:10.14740/jocmr4919] [PMID] [PMCID]
30. Drewes JL, Chen J, Markham NO, Knippel RJ, Domingue JC, Tam AJ, et al. Human colon cancer-derived Clostridioides difficile strains drive colonic tumorigenesis in mice. Cancer Discov. 2022;12(8):1873-85. [DOI:10.1158/2159-8290.CD-21-1273] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc